Stereotactic radiosurgery in the treatment of brain metastases: The current evidence  by Lippitz, Bodo et al.
Cancer Treatment Reviews 40 (2014) 48–59Contents lists available at SciVerse ScienceDirect
Cancer Treatment Reviews
journal homepage: www.elsevierheal th.com/ journals /c t rvAnti-Tumour TreatmentStereotactic radiosurgery in the treatment of brain metastases:
The current evidence0305-7372  2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.
http://dx.doi.org/10.1016/j.ctrv.2013.05.002
⇑ Corresponding author. Address: Gamma Knife Centre, Bupa Cromwell Hospital,
Cromwell Road, London SW50TU, United Kingdom.
E-mail addresses: bodo.lippitz@cromwellhospital.com, bodolippitz@me.com,
bodo.lippitz@karolinska.se (B. Lippitz).Bodo Lippitz a,b,⇑, Christer Lindquist b, Ian Paddick b, David Peterson b,c, Kevin O’Neill b,c, Ronald Beaney b,d
aGamma Knife Center, Karolinska University Hospital, Stockholm, Sweden
bGamma Knife Centre, Bupa Cromwell Hospital, London, United Kingdom
cCharing Cross Hospital, London, United Kingdom
dGuy’s and St. Thomas’ NHS Foundation Trust, United Kingdoma r t i c l e i n f o
Article history:
Received 24 September 2012
Received in revised form 8 May 2013






Linaca b s t r a c t
Chemotherapy has made substantial progress in the therapy of systemic cancer, but the phar-macological
efﬁcacy is insufﬁcient in the treatment of brain metastases. Fractionated whole brain radiotherapy
(WBRT) has been a standard treatment of brain metastases, but provides limited local tumor control
and often unsatisfactory clinical results. Stereotactic radiosurgery using Gamma Knife, Linac or
Cyberknife has overcome several of these limitations, which has inﬂuenced recent treatment recommen-
dations. This present review summarizes the current literature of single session radiosurgery concerning
survival and quality of life, speciﬁc responses, tumor volumes and numbers, about potential treatment
combinations and radioresistant metastases.
Gamma Knife and Linac based radiosurgery provide consistent results with a reproducible local tumor
control in both single and multiple brain metastases. Ideally minimum doses of 18 Gy are applied.
Reported local control rates were 90–94% for breast cancer metastases and 81–98% for brain metastases
of lung cancer. Local tumor control rates after radiosurgery of otherwise radioresistant brain metastases
were 73–90% for melanoma and 83–96% for renal cell cancer. Currently, there is a tendency to treat a
larger number of brain metastases in a single radiosurgical session, since numerous studies document
high local tumor control after radiosurgical treatment of >3 brain metastases. New remote brain
metastases are reported in 33–42% after WBRT and in 39–52% after radiosurgery, but while WBRT is
generally applied only once, radiosurgery can be used repeatedly for remote recurrences or new metas-
tases after WBRT. Larger metastases (>8–10 cc) should be removed surgically, but for smaller metastases
Gamma Knife radiosurgery appears to be equally effective as surgical tumor resection (level I evidence).
Radiosurgery avoids the impairments in cognition and quality of life that can be a consequence of WBRT
(level I evidence). High local efﬁcacy, preservation of cerebral functions, short hospitalization and the
option to continue a systemic chemotherapy are factors in favor of a minimally invasive approach with
stereotactic radiosurgery.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.Introduction inoperable and were left untreated, the median survival was onlyAccording to conservative estimates about 8% of cancer patients
will develop brain metastases,1 which often cause the leading
symptoms. Chemotherapy has signiﬁcantly improved the
prognosis of patients with cancer but generally fails in the treat-
ment of brain metastases. When brain metastases were considered51 days.2 An effective therapy and local tumor control is
paramount for the prognosis the quality of life.
In practice, conventional fractionated whole brain radiotherapy
(WBRT) is still frequently applied as a standard therapy of brain
metastases,3 but side effects and lack of sustained local efﬁcacy
could outweigh potential beneﬁts: The median survival of patients
with brain metastases treated with WBRT ranges between 2.8 and
5.4 months4–12 and was less than 4.5 months in 8 out of 9 studies
in 1925 out of 1971 reported patients. In patients with adverse
prognostic features there was no signiﬁcant difference between
best supportive care and 20 Gy WBRT and only slight and clinically
irrelevant differences in the 30 Gy WBRT group (median 2.2 vs.
1.7 months).13 These results match the recently published interim
data from the QUARTZ Trial (Quality of Life after Radiotherapy for
B. Lippitz et al. / Cancer Treatment Reviews 40 (2014) 48–59 49Brain Metastases), a randomized phase III trial of patients with
inoperable NSCLC brain metastases that showed a median survival
of 49 days after optimal supportive care plus WBRT.2
On the other hand, WBRT must be considered insufﬁcient in
patients with a better systemic prognosis, since prospective and
randomized studies showed that WBRT provided only limited local
control over the treated brain metastases with complete or partial
responses in 24–55%.14,15 WBRT in brain metastases of colorectal
cancer (3 Gy  10) achieved a local control of 17% at 6 months.16
In clinical practice, chemotherapeutical regimens are often discon-
tinued during fractionated radiotherapy of brain metastases.
The application of focal radiation using Gamma knife or Linac
based stereotactic radiosurgery (SRS) has changed these previously
rather negative perspectives in a fundamental way. Reproducible
tumor control after radiosurgery underlines that physically
focused and stereotactically applied radiation can overcome
several limitations of fractionated radiotherapy. This insight
has signiﬁcantly inﬂuenced treatment recommendations17 and
guidelines that have recently been published to deﬁne the criteria
for treatment of brain metastases from a surgical,18 radiotherapeu-
tical19,20 and radiosurgical21 perspective. Larger brain metastases
with a clinically relevant mass effect should be removed surgically
as two prospectively randomized trials found signiﬁcantly
improved survival and functionally independent survival after
surgical resection when compared with fractionated radiotherapy
alone22,23. Single session radiosurgery in larger brain metastases
is generally not recommended due to the increased risk of a later
formation of edema with associated delayed side effects.
In practical terms radiosurgery is still an unusual treatment, as
only 6.1% of 7684 patients with non-small cell lung cancer who
were diagnosed with brain metastases in the US between 2000
and 2007 had billing codes for stereotactic radiosurgery24. Simi-
larly, an international online practice survey that was answered
predominantly by radiation oncologists, showed that 78% of
respondents would still use WBRT alone for initial treatment of
two to four brain metastases in patients with a KPS of 70 and active
extra-cranial disease 3. The use of radiosurgery however, was sig-
niﬁcantly associated with increasing year of diagnosis, higher
socioeconomic status and admission to a teaching hospital 24.
Several most relevant statements deﬁning the role of radiation
therapy in the treatment of brain metastases that have recently
been formulated in an American Society for Radiation Oncology
evidence-based guideline20 reﬂect a changing paradigm and are
summarized below:
1. The addition of fractionated whole brain radiotherapy (WBRT)
after surgical resection of brain metastases does not improve
overall survival or duration of functional independence, but
improves treated brain metastasis control and overall brain
control.20,25,26
2. In patients with good prognosis and single brain metastasis
(<3 cm), either surgery or radiosurgery may be considered.20
3. Selected patients with brain metastasis(es) may be treated with
radiosurgery alone.20
4. Radiosurgery boost added to WBRT in patients with multiple
brain metastases and good prognosis improves control over
treated brain metastases as compared with WBRT alone.20,27,28
5. Two randomized trials showed that omission of WBRT after
radiosurgery is associated with better neurocognitive out-
comes29,20 and with better health related quality of life.30
6. The randomized trial RTOG 950831 found an improvement in
KPS and decreased steroid use at 6 months with the use of
radiosurgery boost added to WBRT, but
7. WBRT alone may be considered, as there is no survival
advantage with radiosurgery added to WBRT in patients with
multiple brain metastases.20Brain tumour control can be essential for the neurologic integrity
and quality of life, but may not always have a direct impact on the
patient’s survival, since the patient’s outcome is determined by the
characteristics and the status of the systemic disease 32–36. In this
situation chemotherapy regains an important role, since it is gener-
ally not disrupted for single session radiosurgery. The validation of
treatment success in the therapy of brain metastases can be com-
plex, since local control of the treated metastasis is not generally
measured in the radiotherapeutical literature and the comparison
of survival rates seems to be insufﬁcient for the determination of
the optimal treatment: Recent studies deﬁned the negative out-
come for patients who were treated with best supportive care only,
hence emphasizing the need for effective treatment of brain metas-
tases.2,13 However, several prospective randomized studies demon-
strated that the overall survival of patients with multiple
metastases appeared to be relatively unaffected by the local control
of brainmetastases: In a recent EORTC study the overall survival did
not differ between the surgery/radiosurgery arms, whenWBRTwas
added or omitted with a median survival of 10.9 months in the
observation arm and 10.7 months in theWBRT arm, althoughWBRT
reduced the probability of relapse at initial sites for the patients
treated with radiosurgery from 31% to 19% and after surgery from
59% to 27% (at 2 years), respectively.26 Similarly, Aoyama showed
in a randomized trial that median survival was 7.5 months in the
WBRT plus stereotactic radiosurgery (SRS) group and 8.0 months
for radiosurgery alone (P = .42), although the 12-month brain tu-
mour recurrence rate was 46.8% in the WBRT plus SRS group and
76.4% for SRS alone group (P < .001) and the actuarial local tumour
control rate at 12 months was 88.7% in the WBRT plus SRS group
and 72.5% in the SRS-alone group (P = .002).28 Patchell had shown
for patients with single brain metastases who were treated with
complete surgical resections and postoperativeWBRT, or no further
treatment, that recurrence of tumor anywhere in the brain was less
frequent in the radiotherapy group (18%) than in the observation
group (70%), but that there was no signiﬁcant difference between
the groups in overall length of survival or the length of time that
patients remained functionally independent.25 In another prospec-
tive randomized study, patients with two to four brain metastases
were randomized to initial brain tumour management with WBRT
alone or WBRT plus Gamma Knife radiosurgery. The study was
stopped at an interim evaluation at 60% accrual, since the rate of
local failure at 1 year was 100% after WBRT alone but only 8% in
patients who had boost radiosurgery. Although there was a trend
in improved median survival in the radiosurgery group, the
difference was not signiﬁcant (11 vs. 7.5 mo).27
The vast majority of the scientiﬁc evidence has been published
on single session radiosurgical treatments, and the current review
focuses entirely on this treatment form, although the American
Society for Therapeutic Radiology and Oncology (ASTRO), the
American Association of Neurological Surgeons (AANS) and the
Congress of Neurological Surgeons (CNS) agreed that stereotactic
radiosurgery typically is performed in a single session, but can be
performed in up to ﬁve sessions.37,38 Despite this deﬁnition, it still
remains to be scientiﬁcally proven that single and multiple session
radiosurgery are clinically equivalent.
The previously simplistic competition between single treatment
technologies has been replaced by comprehensive clinical ques-
tions concerning treatment paradigms: WBRT as routine therapy
for brain metastases is being questioned with all resulting pros
and cons. Highly focused single session radiation is developing as
a new standard. The role of hypofractionated radiosurgery will
have to be deﬁned and is not discussed in the current review. Com-
mon knowledge is changing and more differentiated questions re-
main to be addressed. The present review attempts to summarize
the current literature concerning single session radiosurgery
according to relevant clinical issues concerning survival, quality
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tential treatment combinations and radioresistant metastases also
with respect to standard fractionated radiotherapy. Not all ques-
tions can be answered by a mere comparison of survival rates.
The ongoing discussion requires a detailed evaluation of the evi-
dence in all clinical aspects.
Stereotactic radiosurgery
The principle of radiosurgery implies concentrating radiation
within a tumor while avoiding radiation of the surrounding
healthy tissue (Fig. 1). The Gamma Knife achieves this by mechan-
ical focusing of ca 200 radiation sources, which allows shaping of a
deﬁned irradiated volume in the brain. In the stereotactic Linear
Accelerator (Linac) the radiation beam is shaped by a set of leaves
usually made of a tungsten alloy, the multi-leaf collimator. The po-
sition of each leaf is computer-controlled in order to match the
geometry of the irradiated lesion. The Cyberknife consists of a
small linear accelerator mounted on an industrial robot. The Cyber-
knife’s robotic arm directs small beams of radiation from multiple
angles that converge upon the tumor. Shaping of the radiation ﬁeld
is achieved by a high number of different trajectories. The neces-
sary precision of target localization requires a stereotactic MRI or
CT study before radiosurgery and a stereotactic frame ﬁxation
(for Linac and Gamma Knife). Radiation doses are expressed as
‘‘prescription doses’’ or ‘‘minimum doses’’, reﬂecting the dose ap-
plied to the tumor periphery. Generally, prescription doses of
18–25 Gy are applied in radiosurgery for brain metastases. In Gam-
ma Knife treatments this minimum dose commonly corresponds to
50% of the maximally applied dose (50% isodose) resulting in an
inhomogeneous dose distribution within the tumor, with maxi-
mum doses ranging between 36 and 50 Gy.
Technical accuracy of stereotactic radiosurgery
In the recent Gamma Knife model (Perfexion), the accuracy of
the mechanical versus radiation isocentre was found to be
0.05 mm.39 Including the geometrical error from implementation
of imaging data, the total error in the Gamma Knife system was
calculated to be 0.48 ± 0.23 mm.40 For the Cyberknife, the ideal dy-
namic alignment margins that accommodate for the detection andFig. 1. Typical radiosurgical dose plan (Gamma Knife) for a right frontal metastasis wi
(yellow line) and the 10 Gy isodose (green line).correction precision41,42 have recently been calculated to be
1.5 mm.43 The patient is not frame ﬁxated during the Cyberknife
treatment, hence the accuracy of the treatment depends on the fre-
quency of X-ray based position control measurements, which are
necessary to compensate for the patient’s involuntary movements.
With a frame-based technique, such as the Gamma Knife or a Linac,
precision is easier to determine using phantoms since patient
movements are mechanically avoided. Phantom studies with a ste-
reotactic Linac have shown that a CT localized target can be irradi-
ated with a positional accuracy of 0.8 mm in any direction with
95% conﬁdence.44
Radiation conformity
Radiosurgery avoids the irradiation of healthy tissues. The clo-
ser the prescription dose is matched to the treated target and the
steeper the dose gradient around the target, the less normal tissue
is irradiated. This matching of the dose to a 3-dimensional target is
generally quantiﬁed using the conformity index, which reﬂects the
amount of normal tissue within the prescription isodose (Fig. 1). A
simpliﬁed conformity index is the ratio of prescription volume to
target volume, which would ideally be one, if no healthy tissue
were irradiated. Polymer gel measurements veriﬁed the planned
dose distribution in the most recent Gamma Knife models (Perfex-
ion) with a conformity of 1.17.45 For stereotactic Linac radiosurgery
this conformity index has been reported to range from 2.746 to 1.8
for the micromultileaf collimator.47 Due to its isocentric planning
arrangement it is possible for a Gamma Knife to treat many targets
such as multiple brain metastases in one single session, which can
be technically challenging for Linac and Cyberknife.
Extracranial doses vary depending on the technology used. Due
to effective shielding, Gamma Knife doses decreased steeply with
distance from the treated brain, delivering only 13 mSv at the low-
er pelvis in comparison to 117 and 132 mSv during CyberKnife
treatments.48 Further reduction of extracranial doses has been
shown in the recent Gamma Knife model Perfexion.49
Clinical efﬁcacy
The ﬁrst cases of stereotactic percutaneous single dose radio-
surgical treatments for cerebral metastases had been publishedth high radiation conformity to the target showing the 20 Gy prescription isodose
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ator50 and 1989 by Lindquist after treatment with Gamma Knife.51
Since then an estimate of more than 200,000 radiosurgical treat-
ments for brain metastases have been carried out, the vast majority
with Gamma Knife.
A wide range of retrospective and prospective Gamma Knife
studies with more than 4800 published patients with brain
metastases provide consistent and reproducible results with an
average local tumor control between 84% and 97%52–76 (Fig. 2).
The treatment with stereotactic Linac is often applied with lower
maximum doses when compared to the Gamma Knife but the
clinical results in brain metastases appear to be similar.31 Local
control of metastases treated with Linac is achieved in 85–
91%77–79 and the 1-year tumor control rates range between 69%
and 81%80,81 with lower local control (60%) in tumors larger than
2 cm.82 So far there are too few publications on Cyberknife treat-
ment for brain metastases to allow a comparison, since the tech-
nology is relatively new but recent studies showed a similar local
control of brain metastases.83,84
Chidel found no difference in local or distant relapse of brain
metastases among patients treated with Gamma Knife compared
with stereotactic Linac,85 but systematic comparisons between
radiosurgical treatment facilities are lacking. Detailed analyses
concerning differences in local control, adverse effects, practicabil-
ity and number of treatable metastases will have to be carried out,
but based on the currently available evidence it has to be assumed
that in the treatment of brain metastases clinical results will be
similar in various applied technologies.
Multivariate analysis indicated that longer freedom from pro-
gression was signiﬁcantly associated with higher radiosurgical
dose; local tumor control was superior for metastases treated at
minimum doses of 18 Gy or higher.71 A similar Gamma Knife
study showed that a margin dose of 18 Gy was more likely to pro-
vide tumor reduction and resolution of peritumoral oedema,86
which was also demonstrated for Linac treatments.87 Brain
metastases tend to shrink gradually after radiosurgery; the perifo-
cal oedema disappears after several weeks. Metastases that are
generally resistant to fractionated external beam radiation, such
as melanoma or renal cancer, are successfully treated by stereo-
tactic radiosurgery, which has lead to a paradigm change in the
therapy of these tumors 55,61,88.
The tumor volume is the primary limiting factor in radiosur-
gery since the volume of the irradiated healthy brain in the
penumbra of the metastasis increases when larger metastases
are treated. This can result in formation of a local oedema around
the irradiated target, typically 6–9 months after radiosurgery. This
effect is generally transient, but may require steroid medicationFig. 2. Colon cancer: Gamma Knife treatment of a solitary metastasis: (a) before radi
Transient adverse radiation effect with edema 6 months after treatment and long-termand in rare cases, a surgical intervention. Adverse radiation effects
are generally seen in larger metastases or unconformal treat-
ments and are uncommon when metastases smaller than 2.5 cm
are treated.Breast cancer
Fractionated WBRT for brain metastases of breast cancer
achieved only limited local control with intracranial failure after
a median of 3–5 months.89,90 When radiosurgery was used as
salvage treatment of tumor recurrence after WBRT, the median
survival was 10.3–14 months91–93 (Fig. 3).
Four retrospective analyses after Gamma Knife treatment of
breast cancer metastases with a combined 599 patients reported
high local tumor control rates between 90% and 94%.52,54,93,94 The
prognosis of patients with brain metastases of breast cancer
seems to be slightly superior when compared to other groups of
cancer patients with a median survival between 10 and
16 months.54,94–97 Patients in RPA class I, II, and III survived
34.9, 9.1, and 7.9 months, respectively.94 The improvements of
chemotherapy for breast cancer patients underline the necessity
for an equally effective radiosurgical treatment of these brain
metastases.
The recent analysis (2013) of a multi-institutional retrospective
database of 383 patients with breast cancer demonstrated that tu-
mor subtype is an essential factor resulting in large and signiﬁcant
differences in prognosis: after diagnosis of brain metastases, the
median survival for the patients with the basal subtype (triple neg-
ative), Luminal A (ER/PR positive/HER2 negative), HER2 positive/
ER/PR negative and Luminal B (triple positive) subtype were 7.3,
10, 17.9, and 22.9 months, respectively.32 Another recent study
from the Cleveland Clinic conﬁrmed in 264 radiosurgically treated
breast cancer patients with brain metastases a more favorable out-
come in HER2+ patients relative to those with HER2 breast can-
cer, with a median survival of 31.3 vs. 14.1 months (p < 0.01).98
Similarly, the presence of triple negative phenotype was associated
with worse prognosis with median survival times after Gamma
Knife radiosurgery being 6 vs. 16 months, respectively.33 Most ser-
ies do not deﬁne tumor subtypes; as a consequence it is now difﬁ-
cult to compare their results with respect to survival rates.Lung cancer
Patients with a complete response after multimodality therapy
for locally advanced non-small cell lung cancer (NSCLC) are at high
risk for the subsequent development of brain metastases. Chenosurgery (b) 6 month FU, (c) 9 mo, (d)12 mo, (e)15 mo, (f) 61 months follow-up.
tumor control 5 years after radiosurgery.
Fig. 3. multiple brain metastases from breast cancer: (a) Gamma Knife treatment of six metastases (here pons and left temporal) (b) MR follow- 3.5 years later, asymptomatic
patient.
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of brain metastasis-free survival for patients with squamous and
nonsquamous cancers were 57% and 34%, respectively.99 Median
survival appears to be longer for a subgroup of NSCLC patients with
mutations in the epidermal growth factor receptor that predict un-
ique sensitivity to EGFR tyrosine kinase inhibitors (14.5 vs.
7.6 months, P = .09).35
Local control rates after stereotactic radiosurgery in general
were quite consistent: between 81%,100,101 85%,58 94%56 and
98%.102 Tumor control rates after Gamma Knife radiosurgery varied
depending on the tumor volume: Between 94% for metastases be-
tween 0.5 and 2 cm3 and 85.7% for tumors between 8 and 14 cm,3
respectively64 with better result when minimum doses ofP18 Gy
are applied.87 The median survival for patients with brain metasta-
ses from lung cancer treated with Gamma Knife ranged between 9
and 18 months.56,58,64,70,101–105 A median overall survival of
18 months was reported in solitary brain metastasis from NSCLC
after Gamma Knife treatment plus additional WBRT (in 78%)106,
but generally the combination of WBRT plus Gamma Knife did
not provide better survival than Gamma Knife treatment
alone.64,70,103 The factors: younger age, good performance status,
lung resection, no other systemic metastases, and either tumor
resection or stereotactic radiosurgery predicted best survival.64,107
Gamma Knife appears to be as effective in treating brain metasta-
ses from SCLC as for those from NSCLC.102,108Malignant melanoma
Based on the limited local tumor control rate after WBRT, brain
metastases of malignant melanoma are considered radioresistant.
This restriction does not apply to radiosurgery, since various series
after Gamma Knife radiosurgery of malignant melanoma report
reproducible local tumor control rates between 73% and
90%55,61,62,109–115 and a short-term local control rate of 98% at
3 months.116 A study after both Linac- and Gamma Knife-radiosur-
gery in 31 patients with brain metastases from renal cell carci-
noma, melanoma, or sarcoma showed a 6-month actuarial tumorcontrol of 68.8%.117 One stereotactic Linac study of intracranial
melanoma metastases reported an unusually low one-year local
control of only 42.3% for tumors >2 cc and 75.2% for tumors
62 cc.118 In this study 33% of patients had been treated with pre-
scription doses of <18 Gy,118 which must be considered as a rela-
tively low dose. When the RPA classiﬁcation119,120 was applied in
patients where Gamma Knife radiosurgery was the initial treat-
ment, patients in RPA Class I survived a median of 14.5 months,
compared with a median survival of 5 months for patients in RPA
Class II or III.111 In a combined group of patients with brain metas-
tases of melanoma and renal cell carcinoma, the median survival
was 23.5 months for patients in RPA Class I and 10.5 months for
patients in RPA Class II or III.109 The median survival was
22 months for patients with a solitary brain metastasis of malig-
nant melanoma when the extracranial disease was controlled,
and when immunotherapy was administered after Gamma Knife
treatment.115 The local tumor control rates of melanoma metasta-
ses treated with Linac radiosurgery were 72–84%.80,121,122Renal cell carcinoma
While brain metastases of renal cell carcinoma are considered
unresponsive to fractionated WBRT with a reported survival of
only 3.0–4.4 months,123 Gamma Knife treatment provided local
control rates between 83% and 96%110,124–129 with a resulting med-
ian survival between 9.5 and 13 months.126–130 For Gamma Knife
treated patients in RPA class I, the median survival was 18–
24 months.124,126 Linac radiosurgery resulted in local control rates
of 68–93%.117,121,131 The addition of WBRT did not prevent the
development of new remote tumors in patients with renal cell can-
cer metastases.125,132Colorectal cancer
Local tumor control was achieved in 84–96% in colorectal can-
cer metastases undergoing Gamma Knife radiosurgery while the
B. Lippitz et al. / Cancer Treatment Reviews 40 (2014) 48–59 53addition of WBRT to radiosurgery did not improve survival and lo-
cal tumor control rates.133–136Comparison with open surgery
If neurological symptoms are caused by the mass effect of a lar-
ger metastasis (>8–10 cm,3) the tumor is generally removed with a
surgical resection. The expected median survival after surgery is
5.6–8.5 months137–139, but a good performance status and con-
trolled systemic disease are prerequisites for operability140 and
for potential survival beneﬁts from surgery.17 Local postoperative
tumor recurrences occur in 46–58%25,139,140 and postoperative con-
ventional radiotherapy is applied to reduce this risk.18 However,
this combined approach does not improve the survival time and
is both invasive and time consuming for the patient.25,141 Three
retrospective and one prospective randomized study compared
the efﬁcacy of Gamma Knife radiosurgery of brain metastases with
open microsurgery (plus WBRT).63,69,140,142 Similar to the three ret-
rospective studies, even the prospective randomized study142
showed equivalent outcomes after Gamma Knife radiosurgery vs.
surgical resection plus WBRT as treatment results did not differ
signiﬁcantly in terms of survival, neurological death rates, and
freedom from local recurrence.142 Radiosurgery was associated
with a shorter hospital stay, less frequent and shorter steroid appli-
cation, and lower frequency of toxicities.142 However, the random-
ized study comprises of only 64 patients and has been criticized as
being too underpowered20 for deﬁnite conclusions. In summary,
the therapeutic efﬁcacy of Gamma Knife radiosurgery can be con-
sidered as equivalent to standard surgical approaches in the treat-
ment of smaller brain metastases that do not cause clinically
relevant mass effect.21Multiple metastases
A variety of MRI imaging protocols and even CT are applied in
the diagnosis of brain metastases. Since the resulting number of
detected tumors is directly dependent on the diagnostic
method,143 clinical results can hardly be classiﬁed according to
numbers of treated metastases unless the diagnostic tools are
standardized.
In most patients with multiple metastases, tumors tend to be
small and do not affect the patient via local mass effect. Rather
than the number of metastases, the total tumor volume appears
to have an important inﬂuence on the prognosis.144,145 In general
there is a tendency to treat a larger number of brain metastases
in a single radiosurgical session, since numerous studies document
high local control after radiosurgical treatment of more than three
brain metastases. Gamma Knife treatment in patients with 3–6
brain metastases provided actuarial 2-year control rates of
74.3%.146 Serizawa and Yamamoto published a combined series
of 1508 consecutive cases and reported no difference in survival
between patients with 2–4 and 5–10 brain metastases.147 In an
earlier series of 521 patients treated with Gamma Knife, a similar
outcome in terms of overall and neurological survival was found
for patients with few (63) and many (4–10) brain metastases.148
The number of brain metastases did not have a signiﬁcant impact
on survival,149,150,65,85 which was conﬁrmed after Gamma Knife
treatment of patients with breast52 and renal cancer.132 In a cohort
of 251 patients who had initially been treated with Gamma Knife
alone at the MD Anderson Cancer Center it was shown that the
number of brain metastases was not predictive of distant brain fail-
ure, local control, and overall survival.151 Similarly, in a retrospec-
tive analysis total of 310 patients who had been treated with
Gamma Knife radiosurgery after prior WBRT at the Stanford Uni-
versity School of Medicine there was no relationship between thenumber of brain metastases and survival after excluding patients
with single metastases.152 Patients who had undergone Gamma
Knife radiosurgery at the Yonsei University College of Medicine,
Seoul (n = 323) were divided into groups according to the number
of lesions visible on MR images: Median survival was 10 months
for patients with 1–5 metastases; 10 months for 6–10 lesions,
13 months for 11–15 lesions and 8 months for patients with more
than 15 brain metastases.153 The difference was not statistically
signiﬁcant.
Yamamoto and colleagues recently published a retrospective
cohort study of patients who had undergone stereotactic radiosur-
gery without WBRT and demonstrated that the median survival
time after radiosurgery was 7.9 months in patients with 1–4 brain
metastases (n = 548), and 7 months in patients with more than
four metastases (n = 548) (p = 0.01).154 Some series indicate a less
favorable median survival for patients with more than three155,156
or more than seven metastases,157 but there is no simplistic corre-
lation between the number of metastases and the patient’s progno-
sis. Hence, an increased number of brain metastases can be an
unfavorable factor for longer survival, but the impact on survival
time appears to be rather limited (Fig. 3). There is increasing evi-
dence that other factors such as the subtype of the primary can-
cer32–35 and the state of the systemic disease36 are major
contributing factors for the prognosis.
Patients with more than four brain metastases do not appear to
have an inferior outcome in terms of neurological death, repeat
SRS, maintenance of good neurological state and radiosurgery-re-
lated complications154, but several treatment recommendations
and practice guidelines limit the number of brain metastases that
can be treated with radiosurgery to a virtually arbitrary number
of three or four without consideration of tumor volume or diagnos-
tic method. These recommendations are primarily based on level I
evidence and hence on the available three randomized stud-
ies,27,31,158 where the analysis was limited to patients with less
than 3–4 metastases according to the studies’ selection criteria:
patients with a larger number of metastases had been excluded
from evaluation.
Following a common (mis-)interpretation of the existing data,
radiosurgical treatments are sometimes declined in patients with
more than three metastases despite a realistic option of an effec-
tive local tumor control. However, there is no documented evi-
dence for a lack of radiosurgical efﬁcacy in multiple metastases
or for the existence of another superior treatment for this
condition.Quality of life
Patients receiving stereotactic radiosurgery alone were at sig-
niﬁcantly lower risk of a decline in learning and memory function
by 4 months when compared to patients undergoing additional
WBRT.29 The conclusion from this study was interpreted as level
I evidence to support the use of stereotactic radiosurgery alone.
Fractionated cranial irradiation causes a negative impact on
health-related quality of life scales particularly due to fatigue
and hair loss159 and causes cognitive dysfunction immediately
after the beginning of radiotherapy. Subacute radiation effects on
verbal memory function are observed, both after therapeutic and
prophylactic cranial irradiation.160 These effects were more pro-
nounced in patients with above-average performance at base-
line.160 A recently published prospective randomized EORTC
phase III trial with 359 patients showed that WBRT after surgery
or radiosurgery of brain metastases negatively impacted the
health-related quality-of-life.30 Delayed signiﬁcant CNS toxicity
72 months after fractionated radiotherapy is a known phenome-
non.161 It was shown in a smaller prospective study after Gamma
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remained either unchanged or improved in patients who had no
evidence of intracranial or extracranial tumor progression.162 Qual-
ity of life was also analyzed as part of the prospective randomized
analysis RTOG 95–08. At 6 months follow-up a statistically signif-
icant improvement in clinical performance and decreased steroid
use was found in the stereotactic radiosurgery boost treatment
group when compared with the patients who had been treated
by fractionated radiotherapy only.31Fractionated radiotherapy or stereotactic radiosurgery
Only few studies compared the results after stereotactic
radiosurgery directly with WBRT, but brain control and local
control in Linac treated patients with 1–3 metastases were better
after stereotactic radiosurgery than WBRT for patients in RPA
Classes 1 and 2, whereas overall survival and distant control did
not differ signiﬁcantly.163 A three-arm prospective randomized
clinical trial compared Gamma Knife radiosurgery alone, WBRT
alone or the combination of both in patients with brain metastases
of various primary cancer histologies. The local control was 87%,
91%, and 62% for GK, GK +WBRT and WBRT alone respectively,
suggesting that the outcome of the two radiosurgery arms were
superior.158 NSCLC patients with 1–10 brain metastases were
treated with Gamma Knife radiosurgery or WBRT and neurological
and qualitative survival were shown to be longer for the Gamma
Knife group.164 So far no study after conventional fractionatedFig. 4. A breast cancer: Recurrent multiple brain metastases after WBRT (a) before radio
tumor shrinkage.radiotherapy alone has ever shown superior results regarding local
control or survival.
Three endpoints are important to determine the value of the
combination of fractionated radiotherapy and radiosurgery: (a)
survival, (b) local control of the treated metastases and (c) avoid-
ance of new remote metastases.WBRT plus radiosurgery: endpoint local control
The local control of metastases treated with stereotactic radio-
surgery depends on the minimum tumor dose (prescription dose),
which should be 18 Gy.71 When radiosurgical prescription doses
of less than 16 Gy were given, 27–38% of lesions failed
locally.165,166 With radiosurgical prescription doses >16 Gy, addi-
tional WBRT did not improve local control.166 Several Linac series
treated patients very close to this threshold of efﬁcacy with mean
prescription doses of 16–19 Gy.81,118 Aoyama published a random-
ized controlled trial of patients with 1–4 brain metastases with an
actuarial local tumor control rate of 88.7% at 12 months in the
WBRT + SRS group and 72.5% in the SRS-alone group with similar
preservation of neurologic function in both arms.28 Another Linac
study showed an improvement of 1-year- local control rates in
combination of WBRT + SRS,167 but several large retrospective
studies have not documented any differences in local control of
the radiosurgically treated metastases when WBRT was omit-
ted.53,62,168,169 ASTRO stated in evidence-based guidelines that in
good prognosis patients with multiple brain metastases (<4,
<4 cm), radiosurgery boost when added to WBRT improves treatedsurgery (b) MR-follow-up 3 months after Gamma Knife salvage treatment showing
B. Lippitz et al. / Cancer Treatment Reviews 40 (2014) 48–59 55brain lesion and overall brain control as compared with WBRT
alone.170WBRT plus radiosurgery: endpoint survival
Radiosurgery can be applied for local recurrences or newmetas-
tases after WBRT31,171 (Fig. 4). Chao reported a median survival of
17.7 months in a study with patients undergoing radiosurgery as
salvage after initial WBRT.172 This result appears to be superior
to the vast majority of series of fractionated radiotherapy and of-
fers new therapeutic options in case of failure after WBRT.
A prospective randomized study showed that the radiosurgical
boost in addition to WBRT improved functional autonomy31 and a
multi-institutional retrospective study of 502 patients treated with
WBRT and stereotactic radiosurgery boost (Linac or Gamma Knife)
showed a median survival of 16.1, 10.3, and 8.7 months for RPA
classes I, II, and III, respectively. The results were interpreted as a
survival beneﬁt in favor of the stereotactic radiosurgical boost
when compared to historical RTOG data after WBRT.66 In his ran-
domized trial, Aoyama reported a median survival of 7.5 months
in the WBRT + SRS group and 8.0 months for SRS alone.28 Similarly,
a retrospective Linac series showed no signiﬁcant difference in
1-year-survival (53% vs. 56%) after SRS or WBRT + SRS.167 Data
from 10 institutions were used to compare survival probabilities of
patients with brain metastases managed initially with stereotactic
radiosurgery (SRS) alone vs. SRS + WBRT: The result was that
omission of up-front WBRT did not compromise length of survival
in patients treated with radiosurgery,73 which was supported by
others.150,167,173
Chidel analyzed the differentiated effect of the timing of frac-
tionated radiotherapy after radiosurgery and found that patients
treated with SRS who were treated with delayed WBRT at the time
of a progression had the longest median survival (11.6 mo) when
compared to patients with SRS and immediate WBRT. Differences,
however, were not signiﬁcant.85 Prior WBRT might increase the
risk for peritumoral edema in patients after radiosurgery86
(Fig. 2) representing a potential contraindication only in large
metastases.WBRT and radiosurgery: endpoint distant failure
Since radiosurgery is a local treatment, a prophylactic effect
against potential future brain metastases cannot be expected.
Radiosurgically treated patients experience new metastases out-
side the initial target area in 39–52%,85,158,174 when usually a
new radiosurgical treatment remains an option.75 Fractionated
whole brain radiotherapy has been recommended to avoid new
distant brain metastases. The theoretical argument was the in-
tended treatment of the assumed microscopic disease in multiple
metastases. However, several studies demonstrated that new dis-
tant brain metastases appear despite WBRT. A randomized con-
trolled trial showed that even for patients who had been treated
with fractionated whole brain radiotherapy (+SRS) the 12-month
actuarial rate to develop new brain metastases was 41.5%.28 Chao
showed that 45% of patients failed >6 months after WBRT.172
Others reported new metastases after WBRT in 34%.163 In renal cell
cancer new metastases occurred both in radiosurgically and
conventionally irradiated patients (46% vs. 50%).125 The recent
prospective randomized EORTC study 22,952–26,001 documented
new distant brain metastases after radiosurgery (2-year relapse
rate) in 33% of patients who had been treated with WBRT.26
Although the risk for new brain metastases at distant sites is ca
15% lower after WBRT,26 WBRT will not prevent new tumors. Con-
sequently, new brain metastases must be expected in a consider-
able amount of patients despite WBRT. In this situation, WBRTcan rarely be repeated while salvage radiosurgery remains an op-
tion.91–93,172
Summary
While the prognosis of patients with brain metastases depends
primarily on the status of the systemic disease and hence on effec-
tiveness of a systemic therapy, chemotherapies are still not sufﬁ-
ciently reliable as treatment options for brain metastases.
Rapidly increasing evidence demonstrates that stereotactic radio-
surgery provides highly effective and predictable local tumour con-
trol for single and multiple brain metastases. This accounts even
for conventionally radioresistant metastases frommelanoma or re-
nal cancer. Gamma Knife represents the largest amount of pub-
lished data, but so far there is no scientiﬁc evidence for clinical
superiority of any technology in the treatment of brain metastases.
Empirical dose and volume thresholds have been established for
single session radiosurgery with low risk for side effects or local
recurrences. Minimum doses of 18 Gy and a high radiation con-
formity should be applied. After radiosurgery, the reported local
tumor control rates are 90–94% for brain metastases from breast
cancer and 81–98% for brain metastases from lung cancer. In con-
ventionally radioresistant brain metastases, local tumor control
rates after radiosurgery are 73–90% for melanoma and 83–96%
for renal cell cancer. Avoidance of WBRT can have a positive impact
on the patient’s cognitive status and health related quality of life
(level I evidence). Hence, stereotactic radiosurgery can contribute
to the patient’s preserved functional integrity, when it replaces
WBRT. There is a tendency to treat a larger number of brain metas-
tases in a single radiosurgical session, since numerous studies doc-
ument high local control after Gamma Knife treatment for >3 brain
metastases. New remote brain metastases are reported in 33–42%
after WBRT and in 39–52% after radiosurgery. Radiosurgery can be
applied for local recurrences or new metastases after WBRT. While
larger metastases (>8–10 cc) should be resected, Gamma Knife is
equally effective as surgical approaches in treatment of smaller
metastases (level I evidence). Radiosurgery can be repeated for
new metastases provided the tumour volume remains below
established limits. Hence radiological follow-up of treated patients
with brain metastases is paramount.
Conﬂict of interest statement
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